TSLP and asthma: The fundamental role of TSLP in asthma pathogenesis was underscored by the fact that in 2021, US FDA approved tezepelumab (Tezspire), a human monoclonal antibody (IgG2λ) that inhibits the interaction of TSLP with its heterodimeric receptor, for SA treatment [149].